Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-16 00:41 | 2025-12-11 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; PRESIDENT, CEO AND DIRECTOR | Pharmaceutical Preparations | BUY | $21.75 | 22,000 | $478,496 | 167,000 | +15.2% |
| 2024-08-13 16:04 | 2024-08-12 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; PRESIDENT, CEO AND DIRECTOR | Pharmaceutical Preparations | BUY | $13.01 | 100,000 | $1,300,610 | 145,000 | +222.2% |
| 2023-03-13 23:08 | 2023-03-10 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; PRESIDENT, CEO AND DIRECTOR | Pharmaceutical Preparations | BUY | $9.60 | 15,000 | $143,972 | 45,000 | +50.0% |
| 2022-09-09 23:30 | 2022-09-09 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; PRESIDENT, CEO AND DIRECTOR | Pharmaceutical Preparations | BUY | $14.54 | 30,000 | $436,146 | 30,000 | +100.0% |
| 2021-08-11 20:14 | 2021-08-11 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; President, CEO & Director | Pharmaceutical Preparations | BUY | $29.70 | 16,850 | $500,445 | 568,577 | +3.1% |
| 2019-09-05 14:18 | 2019-09-04 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; President, CEO & Director | Pharmaceutical Preparations | BUY | $26.55 | 75,750 | $2,011,163 | 470,006 | +19.2% |
| 2019-03-14 01:06 | 2019-03-11 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; Presiident, CEO & Director | Pharmaceutical Preparations | BUY | $0.00 | 37,301 | $0 | 129,538 | +40.4% |
| 2018-09-26 23:21 | 2018-09-24 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Director, Officer; President, CEO and Director | Pharmaceutical Preparations | BUY | $24.00 | 22,000 | $528,000 | 22,000 | +100.0% |
| 2018-05-03 23:34 | 2018-05-03 | LLY | ELI LILLY & Co | Simmons Jeffrey N | Officer; SVP&Pres. Elanco Animal Health | Pharmaceutical Preparations | OPT+S | $78.50 | 9,027 | $708,620 | 135,458 | -6.2% |
| 2018-02-06 02:37 | 2018-02-05 | LLY | ELI LILLY & Co | Simmons Jeffrey N | Officer; SVP&Pres. Elanco Animal Health | Pharmaceutical Preparations | OPT+S | $81.12 | 9,625 | $780,780 | 133,201 | -6.7% |
| 2017-12-13 23:01 | 2017-12-11 | LLY | ELI LILLY & Co | Simmons Jeffrey N | Officer; SVP&Pres. Elanco Animal Health | Pharmaceutical Preparations | SALE | $86.46 | 12,500 | $1,080,750 | 124,522 | -9.1% |
| 2015-06-01 23:31 | 2015-05-29 | LLY | ELI LILLY & Co | Simmons Jeffrey N | Officer; SVP&Pres. Elanco Animal Health | Pharmaceutical Preparations | SALE | $78.08 | 20,000 | $1,561,600 | 93,856 | -17.6% |
| 2013-05-13 22:37 | 2013-05-10 | LLY | ELI LILLY & Co | Simmons Jeffrey N | Officer; SVP&Pres.,Elanco Animal Health | Pharmaceutical Preparations | SALE | $54.49 | 10,000 | $544,900 | 51,750 | -16.2% |
| 2012-02-15 20:08 | 2012-02-13 | LLY | ELI LILLY & Co | Simmons Jeffrey N | Officer; SVP&Pres.,Elanco Animal Health | Pharmaceutical Preparations | SALE | $38.85 | 7,900 | $306,915 | 27,182 | -22.5% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.